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a b s t r a c t
Amino acid/diphosphine ruthenium complexes, of general formula [Ru(AA-H)(dppb)(bipy)]PF6 [AA = a-
mino acid: glycine (gly), L-alanine (ala), L-tyrosine (tyr), L-methionine (met), L-leucine (leu), L-valine
(val), L-serine (ser), L-tryptophan (trp), and L-lysine(lys); dppb = 1,4-bis(diphenylphosphino)butane;
bipy = 2,20-bipyridine], were synthesized and characterized. The X-ray structures of the glycine and leu-
cine complexes showed that the amino acids are coordinated to the metal center through the carboxylate
and amine groups. The complexes, except for the glycine ligand, form two different conformational iso-
mers, as suggested by X-ray structure determination of the complex with leucine, and shown by 31P{1H}
NMR analysis. The cyclic and differential pulse voltammograms of the complexes exhibited an oxidation
potential (RuII/RuIII) close to 1.0 V, against Ag/AgCl. Toxicity tests against the MDA-MB-231 and DU 145
human tumor cell lines and the Ehrlich mouse cell line indicated a high degree of cytotoxicity for the
amino acid complexes. The intrinsic binding constants (Kb) for the amino acid complexes were deter-
mined and found to be in the range of 1.40  104–1.80  104 M1, suggesting weak interactions of the
complexes with DNA.
 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Until now, metal-based drugs used in cancer treatment have
been restricted to Pt compounds, with DNA as the main target.
Alternative compounds containing Ru, Ga and Ti have become
the subject of intense investigation in cancer research [1,2]. Ruthe-
nium compounds are of particular interest as they should have a
mechanism of action different from that of Pt antitumor agents.
Ruthenium should also offer reduced toxicity, since its chemistry
similar to that of iron, making it able to bind biomolecules such
as transferrin [3]. Thus, there are some ruthenium complexes with
remarkably low general toxicity, in preclinical or clinical trials,
which show efﬁcacy against several kinds of cancer and metastases
[4–7]. Recently our research group has published some results
showing that ruthenium/diphosphine complexes are promising
as potential anticancer drugs; and here we present some ruthe-
nium/diphosphine/amino acid complexes that also displayed good
cytotoxic activity against the tumor cells MDA-MB-231, DU-145
(human), and Ehrlich (mouse), but lower activity against healthy
cells (L-929, mouse) [7].
In the literature, there are some reports on compounds with the
general formula [Ru-(diimine)2(AA-H)]+ (diimine = 1,10-phenan-
throline or 2,20-bipyridine; AA = optically active amino acid), for
which diastereoisomeric pairs have been isolated, under conver-
sion reactions in the light, according to the equation [8–12]:
D ½RuðdiimineÞ2ðAAHÞþ¢K ½RuðdiimineÞ2ðAAHÞþ ð1Þ
Here, we wish to describe a class of Ru(II)-amino acid com-
plexes that, unlike those diimine/ruthenium complexes, do not suf-
fer light-catalysed inversion of their diastereomers.
The design of the [Ru(AA-H)(dppb)(bipy)]PF6 [dppb = 1,4-
bis(diphenylphosphino)butane; AA-H = deprotonated aminoaacid]
complexes took into account the fact that phosphines are p
acceptor ligands that stabilize the ruthenium(II) ion and that
amino acids, as biomolecules, are well recognized by human or
http://dx.doi.org/10.1016/j.poly.2014.07.024
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mouse cells, making the complexes attractive to them. The 2,20-
bipyridine was used to complete the coordination sphere of the
metal center, and also to help to stabilize the complexes. This
kind of complex, [Ru(AA-H)(dppb)(bipy)]PF6, can exist as two
diastereomers, as in Fig. 1.
Thus, one aim of this work was also to show that the diastereo-
mers (K and D) of the Ru(II)/diphosphine/amino acids complexes
exhibit cytotoxic activities against the MDA-MB-231 and DU 145
human tumor cell lines and the Ehrlich mouse cell line
2. Experimental
2.1. Chemicals
All manipulations were carried out under puriﬁed argon using
standard Schlenk technique. Reagent grade solvents were appro-
priately distilled and dried before use. The RuCl3.xH2O, NH4PF6,
1,4-bis(diphenylphosphino)butane (dppb), 2,20-bipyridine (bipy),
highly polymerized CT-DNA and Tris–HCl (5 mM Tris–HCl and
50 mMNaCl, pH 7.4). were purchased from Aldrich. The concentra-
tion of the DNA nucleotides was determined by UV absorption
spectroscopy, using the molar absorption coefﬁcient
(e = 6600 M1 cm1) at 260 nm [13]. The stock solution was stored
at 4 C. The amino acids glycine (gly), L-alanine (ala), L-tyrosine
(tyr), L-methionine (met), L-leucine (leu), L-valine (val), L-serine
(ser), L-tryptophan (trp), and L-Lysine(lys), were purchased from
Strem. The starting complex, cis-[RuCl2(dppb)(bipy)], was prepared
as described in the literature [14].
2.2. Apparatus
Elemental analyses (C, H and N contents) were recorded in an
EA1108 Fisions Instrument CHNS microanalyzer, at the Microana-
lytical Laboratory of Universidade Federal de São Carlos (São Car-
los, Brazil). Cyclic voltammetry (CV) experiments were carried
out at room temperature in CH2Cl2 containing 0.100 M tetrabutyl-
ammonium perchlorate (TBAP Fluka Purum) using a BAS-100B/W
Bioanalytical Systems Instrument. The working and auxiliary elec-
trodes were stationary Pt foils; the reference electrode was Ag/
AgCl, in a Luggin capillary probe, a medium in which ferrocene is
oxidized at 0.43 V (Fc+/Fc). The voltammograms were performed
at a scan rate of 0.100 V s1, at 25 C. The IR spectra of the com-
plexes were recorded on a FTIR Bomem-Michelson 102 spectrom-
eter in the 4000–200 cm1 region using solid samples pressed in
CsI pellets. The electronic spectra were recorded in CH2Cl2 solu-
tions on a Hewlett–Packard diode array model 8452A spectropho-
tometer. 31P{1H} NMR experiments were recorded on a BRUKER 9.4
T spectrometer (400 MHz for hydrogen frequency) in CH2Cl2, using
a capillary containing D2O.
All the UV–Vis spectra for DNA-complex interactions were col-
lected with the HP 8452A diode array spectrophotometer. Solu-
tions of CT-DNA and complexes were scanned in a 1 cm quartz
cuvette. All absorbance measurements were carried out with a
ﬁxed concentration of DNA (4.5  103 mol L1), while the com-
plex concentration varied from 1.0  105 mol L1 to 3.5  105 -
mol L1. The intrinsic binding constants of interaction of the
complexes with DNA were calculated by the neighbor exclusion
model [15]. It was not possible to dissolve any of the complexes
directly in aqueous phosphate buffer, but all the complexes were
very soluble in DMSO, and the presence of 1–2% DMSO proved suf-
ﬁcient to solubilize them in either pH 7.4 phosphate buffer or PBS.
In these solutions all complexes were stable for at least 72 h. A
Rayonet reactor with seventeen lamps (RPR-4190 or RPR-5750)
was used to test for the possible photochemical reaction.
2.3. X-ray crystallography
Orange crystals of the isolated complexes
[Ru(gly)(dppb)(bipy)]PF63/2(H2O) (1) and [Ru(leu)(dppb)(bipy)]
PF61/2(CH3OH) (2) were grown by slow evaporation of metha-
nol/diethyl ether solutions. The crystals were mounted in an
Enraf–Nonius Kappa-CCD diffractometer with graphite monochro-
mated Mo Ka (k = 0.71073 Å) radiation. The ﬁnal unit cell parame-
ters were based on all reﬂections. Data were collected with the
COLLECT program [15]. Integration and scaling of the reﬂections
were performed with the HKL Denzo-Scalepack suite of programs
[16]. Gaussian or semi-empirical corrections from equivalents
absorption were carried out [17]. The structures were solved by
direct methods with SHELXS-97 [18]. The models were reﬁned by
full-matrix least squares on F2 by means of SHELXL-97 [19]. All
hydrogen atoms were stereochemically positioned and reﬁned
with the riding model. The thermal ellipsoid representations, at
50% probability, shown in Figs. 2 and 3 were prepared with
ORTEP-3 for Windows [20]. Disordered anions and lattice solvent
molecules have been omitted from the ﬁgures for clarity. This dis-
ordered species were treated as sum of occupancy for F atoms. The
collected data and some experimental details are summarized in
Table 1.
Fig. 1. Diastereomers of [Ru(Ala)(dppb)(bipy)]PF6, derived from the chirality of the
glycinato ion.
Fig. 2. ORTEP view of the cation [Ru(gly)(dppb)(bipy)]+ with labeled atoms at the
50% probability level.
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2.4. Cell culture and cytotoxicity assay
In vitro cytotoxicity assays on cultured human tumor cell lines
still represent the standard method for the initial screening of anti-
tumoral agents. Thus, as a ﬁrst step in assessing the pharmacolog-
ical properties of the new ruthenium complexes, they were
assayed with the MDA-MB-231 (human breast), DU 145 (human
prostate), Ehrlich (mouse sarcoma) tumor cell lines and the L-
929 mouse ﬁbroblast cell line. The cells were routinely cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
Fig. 3. ORTEP view of cation [Ru(leu)(dppb)(bipy)]22+ with labeled atoms at the 50% probability level. Right: K diastereoisomer (a); left: D diastereoisomer (b).
Table 1
Crystallographic data for the complexes [Ru(gly)(dppb)(bipy)]PF63/2(H2O) and {[Ru(leu)(dppb)(bipy)](PF6)}2.2(CH3OH).
Formula (C40H41N3O2P2Ru)PF63/2(H2O) (C88H96N6O4P4Ru2)(PF6)22(CH3OH)
Formula weight 929.75 1981.75
T (K) 293(2) 293(2)
Crystal system monoclinic triclinic
Space group P21/c P1
a (Å) 14.8055(3) 10.653(5)
b (Å) 13.2182(4) 13.890(5)
c (Å) 21.7925(4) 15.313(5)
a () 90.000(0) 85.195(5)
b() 98.791(2) 83.340(5)
c () 90.000(0) 86.618(5)
V (Å3) 4214.74(17) 2239.9(15)
Z 4 1
qcalcd (Mg m3) 1.465 1.469
Absorption coefﬁcient (mm1) 0.554 0.525
F(000) 1900 1020
Crystal size (mm) 0.15  0.14  0.11 0.25  0.22  0.09
Method/h range for data collection () 3.12–27.01 2.947–25.411
Index ranges 18 6 h 6 17, 16 6 k 6 15, 26 6 l 6 27 12 6 h 6 12, 16 6 k 6 16, 18 6 l 6 18
Absorption correction GAUSSIAN semi-empirical from equivalents
Reﬂections collected 26669 40719
Reﬂections unique (Rint) 8589 (0.0589) 15657 (0.0684)
Completeness to theta 99.3 99.7
Data/restraints/parameter (%) 8589/0/577 15657/6/1132
Maximum/minimum transmission 0.956 and 0.912 0.952 and 0.871
Final R indices [I > 2r(I)]a,b R1 = 0.0472, wR2 = 0.1206 R1 = 0.0499, wR2 = 0.1274
R indices (all data) R1 = 0.0824, wR2 = 0.1380 R1 = 0.0616, wR2 = 0.1396
GOF on F2, S 1.029 1.030
Largest diff. peak and hole (e.Å3) 0.583 and 0.649 0.608 and 0.842
a R1 =
P
||Fo| – |Fc||/
P
|Fo|.
b wR2 = [
P
w(|Fo|2 – |Fc|2)2/
P
w|Fo2|2]1/2.
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with 10% fetal bovine serum (FBS), at 37 C in a humidiﬁed atmo-
sphere with 5% CO2 atmosphere. After reaching conﬂuence, the
cells were detached by trypsinization and counted. For the cytotox-
icity assay, 4  104 cells were seeded in 200 lL of complete med-
ium per well in 96-well microplates (Corning Costar). The plates
were incubated at 37 C in 5% CO2 for 24 h, to allow cell adhesion
prior to drug testing. The complexes, the cisplatin and the free
ligands were dissolved at 2 mM in sterile DMSO to give the stock
solutions, which were diluted in DMSO to 1.5, 1.0, 0.5, 0.2, 0.1,
0.05 and 0.02 mM. Aliquots of 2 lL of each of these complex solu-
tions were added to 200 lL medium (without FBS), so that the ﬁnal
concentration of DMSO in each well was approximately 1% and the
complex was diluted approximately 100 times. Cells were exposed
to the complex for 48 h. Cell respiration, as an indicator of cell via-
bility, was detected by the mitochondrial reduction of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to a for-
mazan [21]. MTT solution (0.5 mg/mL) was added to cell cultures
and incubated for a 3 h. Thereafter, 100 lL of isopropanol was
added, in order to dissolve the formazan crystals. The conversion
of MTT to formazan by metabolically viable cells was monitored
by an automated microplate reader at 570 nm. The percent cell via-
bility was calculated by dividing the average absorbance of the
cells treated with the ruthenium complex by that of the control;
% cell viability vs drug concentration (logarithmic scale) was plot-
ted to determine the IC50 (drug concentration at which 50% of the
cells are viable relative to the control), the error being estimated
for the average of 3 trials.
At this point, it should be mentioned that the amino acid com-
plexes do not react with dimethyl sulfoxide for a period of at least
48 h, as was demonstrated by 31P{1H} measurements.
2.5. Preparation of complexes
Typically, the complexes were synthesized by reacting the pre-
cursor, cis-[RuCl2(dppb)(bipy)] (0.09 g, 0.1 mmol), dissolved in
25 mL of methanol, with excess of the amino acid (0.170 mmol).
The amino acids were ﬁrst dissolved in a minimal volume of hot
water and slowly dripped into the methanol solution. The solution
was reﬂuxed and stirred for 3 h and NH4PF6 (0.025 g, 0.16 mmol)
was added. After that, the solvent was removed under vacuum,
and dichloromethane (5 mL) was added to dissolve the complex.
This solution was ﬁltered off, its volume was diminished to about
2 mL and diethyl ether was added, yielding an orange precipitate,
which was ﬁltered off, washed thoroughly with water and diethyl
ether, and dried under vacuum. The yield of these syntheses was
about 85–90%: (1), 87%; (2), 85%; (3); 83%; (4), 89%; (5), 90%; (6),
84%; (7), 86%; (8), 87%; (9), 85%. For the synthesis of the tyrosine
complex, ethanol was used instead of methanol.
The data from microanalysis (C, N, H, S) of the complexes are in
Table 2.
3. Results and discussion
3.1. Synthesis of the complexes
The chemical reactivity of the L-amino acids with the precursor
cis-[RuCl2(dppb)(bipy)] enabled the complexes. of general formula
[Ru(AA-H)(dppb)(bipy)]PF6, to be synthesized by simply mixtures
of the reactants, using methanol or ethanol as solvent, dissolving
the amino acid in a small amount of water.
3.2. Structural studies
The X-ray structures of the [Ru(gly)(dppb)(bipy)]PF6 and
[Ru(leu)(dppb)(bipy)] PF6 complexes were determined, and their
ORTEP views, showing the atom numbering schemes, are projected
in Figs. 2 and 3, respectively. Selected bond lengths (Å) and angles
(o) for the complexes are listed in Table 3.
The bond distances and angles found for both structures are in
the expected range of values for octahedral ruthenium(II) com-
plexes, according the statistic analysis performed using Mogul
[22,23]. The reﬁnement of the crystal of [Ru(leu)(dppb)(bipy)]+ in
the non-centrosimetric space group P1, instead of the centrosimet-
ric one P1 can be explained by the fact that while the asymmetric
unit possesses two diastereoisomers, the chirality of the leucine
Table 2
Microanalysis data for the [Ru(AA-H)(dppb)(bipy)] complexes.
Complex C% N% H%
[Ru(gly)(dppb)(bipy)]PF6 (1)C40H41F6N3O2P3Ru 53.16(53.20) 4.65(4.70) 4.57(4.52)
[Ru(leu)(dppb)(bipy)]PF6 (2)C44H48F6N3O2P3Ru 55.12(54.97) 4.38(4.40) 5.05(5.21)
[Ru(tyr)(dppb)(bipy)]PF6 (3)C47H46F6N3O3P3Ru 55.95(55.92) 4.17(4.20) 4.60(4.70)
[Ru(ala)(dppb)(bipy)]PF6 (4)C41H42F6N3O2P3Ru 53.71(53.67) 4.58(4.52) 4.62(4.80)
[Ru(met)(dppb)(bipy)]PF6* (5)C43H46F6N3O2P3SRu 52.87(52.58) 4.30(4.35) 4.75(4.47)
[Ru(ser)(dppb)(bipy)]PF6 (6)C41H42F6N3O3P3Ru 52.79(52.82) 4.50(4.43) 4.54(4.60)
[Ru(trp)(dppb)(bipy)]PF6 (7)C49H47F6N4O2P3Ru 57.03(57.06) 5.43(5.40) 4.59(4.64)
[Ru(lys)(dppb)(bipy)]PF6 (8)C44H40F6N4O2P3Ru 54.78(54.21) 4.18(4.17) 5.81(5.75)
[Ru(val)(dppb)(bipy)]PF6 (9)C43H48F6N3O2P3F6 53.81(53.86) 4.38(4.42) 5.04(5.18)
* S%, calc(exptl): 3.28(3.1).
Table 3
Selected bond lengths (Å) and angles () for complexes [Ru(gly)(dppb)(bipy)]PF6 and
[Ru(leu)(dppb)(bipy)]PF6.
[Ru(gly)(dppb)
(bipy)]PF6
[Ru(leu)(dppb)
(bipy)]PF6
Molecule a Molecule b
Bond lengths
Ru–O(1) 2.080(3) 2.066(10) 2.109(11)
Ru–N(2) 2.080(3) 2.034(13) 2.096(11)
Ru–N(3) 2.095(3) 2.066(13) 2.134(11)
Ru–N(1) 2.179(3) 2.160(12) 2.223(12)
Ru–P(2) 2.3139(9) 2.335(4) 2.328(4)
Ru–P(1) 2.3165(9) 2.325(4) 2.327(4)
O(1)–C(1) 1.268(5) 1.263(17) 1.287(18)
O(2)–C(1) 1.244(5) 1.267(18) 1.20(2)
Angles
O(1)–Ru–N(2) 166.67(11) 167.7(4) 167.1(5)
O(1)–Ru–N(3) 89.24(12) 89.8(5) 89.0(5)
N(2)–Ru–N(3) 78.34(12) 78.2(5) 78.9(5)
O(1)–Ru–N(1) 78.27(12) 78.1(4) 77.2(5)
N(2)–Ru–N(1) 95.29(12) 97.4(5) 97.3(5)
N(3)–Ru–N(1) 83.28(12) 83.5(5) 85.3(5)
O(1)–Ru–P(2) 87.38(8) 92.7(3) 91.7(3)
N(2)–Ru–P(2) 104.34(8) 98.5(3) 99.7(3)
N(3)–Ru–P(2) 172.29(8) 169.5(4) 172.2(4)
N(1)–Ru–P(2) 89.24(9) 87.0(4) 87.3(3)
O(1)–Ru–P(1) 98.69(8) 96.8(3) 97.9(3)
N(2)–Ru–P(1) 86.62(8) 86.4(4) 86.3(3)
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chiral carbons, C2A and C2B, are L in both diastereoisomers, and
therefore the two molecules in the asymmetric unit are not
superimposable.
It is interesting to note that despite of the fact that all amino
acids used were L-diastereomers, their 31P{1H} spectra, in solution,
showed two pairs of doublets, except for the spectrum of the gly-
cine ligand, which has no chiral carbon in its structure (see discus-
sion below). Since the 31P{1H} NMR spectra of all the other amino
acid complexes synthesized here show the same two pairs of dou-
blets, it is reasonable to suggest that all their structures are similar
to that obtained for the complex with leucine. It is also worth men-
tioning that none of the 31P{1H} NMR spectra of the amino acid
complexes change after leaving them under light [white light, ﬁf-
teen RPR-4190 lamps (emission maximum at 420 nm) or ﬁfteen
RPR-5750 lamps (emission maximum at 575 nm)], for at least 12 h.
3.3. Characterization
The infrared spectra of pure samples of [Ru(AA-
H)(dppb)(bipy)]+ complexes in CsI showed typical peaks for the
ligands. The carboxylate stretching frequencies (asymmetric and
symmetric) of the complexes are listed in Table 4.
The difference between the symmetrical and asymmetrical fre-
quencies of the carboxylates groups of the coordinated amino acids
shows that they are unidentate coordinated to the metal center,
functioning as bidentate chelating ligands via one O- and one N-
donor atom, as showed by the X-ray structures, as can be seen in
Figs. 2 and 3, above [24].
The 31P{1H} NMR spectra of the amino acid complexes show
four doublets of type AB, except the complex with glycine, which
shows only two doublets (Fig. 4).
Table 4
Spectroscopic and electrochemical data of complexes (1–9).
Complex 31P{1H} (2Jp–p Hz) masCOO; msCOO (cm1) D* UV–Vis, kmax (e,mol1.L.cm1) Epa (mV) E1/2 (mV)
(1) 45.7; 38,5(32.4) 1616;1434 182 292(25198) 420(3955) 493(1842) 1088 1040
(2) 46.4; 38.8(32.4) 43.9; 39.2(34.1) 1615;1431 184 293(21320) 418(3194) 466(1918) 1077 1002
(3) 46.4; 38.6(34.0) 41.8; 37.8(32.6) 1620;1435 185 293(27733) 427(4229) 485(2401) 1102 1013
(4) 47.5; 39.3(32.4) 45.4; 39.0(32.4) 1623;1434 189 288(27213) 420(3886) 497(1557) 1114 1054
(5) 47.8; 38.6(32.7) 43.6; 38.8(48.6) 1625;1431 194 294(29567) 427(4115) 487(1912) 1045 1045
(6) 48.1; 40.6(36.5) 45.7; 40.8(37.4) 1616;1437 179 292(29263) 421(4735) 481(2055) 1148 1062
(7) 48.2; 40.7(36.6) 45.9; 41.0(37.8) 1614;1435 179 2913(28733) 426(4200) 482(2391) 1122 1060
(8) 48.5; 40.9(36.8) 45.6; 41.1(37.9) 1613;1437 176 291(27633) 427(4439) 484(2391) 1077 1017
(9) 48.3; 40.6(36.5) 45.7; 41.1(37.6) 1615;1439 176 292(26633) 428(4339) 485(2391) 1130 1096
* Difference between two frequencies of carboxylate stretching modes.
Fig. 4. The NMR 31P{1H} of (a) [Ru(gly)(dppb)(bipy)]PF6, in CH2Cl2/D2O; (b) [Ru(15Ngly)(dppb)(bipy)]PF6, in CD3OD and (c) [Ru(ser)(dppb)(bipy)]PF6, in CH2Cl2/D2O.
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In Fig. 4b there is the 31P{1H} NMR spectrum of the complex
[Ru(15N-gly)(dppb)(bipy)]PF6. From these spectra it can be con-
cluded that the shifts at about 39 ppm belongs to the phosphorus
atom trans to the nitrogen of the amino acid, while the signal close
to 45 ppm belongs to the phosphorus atom trans to the nitrogen in
the 2,20-bipyridine ligand. The chemical shifts of the 31P {1H} NMR
spectra of the complexes (1–9) are in Table 4.
For the complex with the serine ligand the two diastereoiso-
mers were separated by HPLC and their NMR spectra are shown
below, in Fig. 5. The chromatogram of the mixture of
[Ru(ser)(dppb)(bipy)]PF6 showed the presence of two species. A
sample of 5 lL was separated on an ODS-C18 column (5 mm;
250  4.6 mm; Shimadzu), eluted isocratically with methanol/
water (57/43 v/v), pH 3.5, at 1 mL min1.
The electronic absorption spectra of 1–9 were recorded at room
temperature using CH2Cl2 solvent. The absorption spectra of the
complexes are similar, exhibiting three bands. The most intense
absorption, at around 290 nm, is assigned to the intraligand transi-
tion. These bands were also observed in the spectra of the free
ligands, in the same solvent. The other two less intense and
lower-energy absorptions, at around 420 and 490 nm, are assigned
to the metal-to-ligand charge transfer (MLCT) dp(Ru)? p⁄ (ligand)
transitions (see data in Table 4).
The [Ru(AA-H)(dppb)(bipy)]PF6 complexes were also character-
ized by cyclic voltammetry and differential pulse voltammetry.
Fig. 6 shows the cyclic voltammogram of the complex [Ru(L-
ser)(dppb)(bipy)]PF6.
All complexes with the general formula [Ru(AA-
H)(dppb)(bipy)]PF6 showed a quasi-reversible electrochemical
process at about 1100 mV, belonging to the oxidation of RuII/RuIII,
and at about 1400 mV, which can be assigned to the oxidation of
the coordinated amino acids, as suggested by literature data (see
Table 4) [25]. Both conformational isomers of the complexes show
the same or a very similar oxidation potential for RuII/RuIII, not dis-
tinguishable by cyclic voltammetry, which was conﬁrmed by dif-
ferential pulse voltammetry, using the isolated diastereoisomers.
In Fig. 7 there are the differential pulse voltamograms of the iso-
lated fractions of the [Ru(ser)(dppb)(bipy)]PF6 complex, where
can be seen the two separated processes can be seen.
It is interesting to point out that the redox potential of the ﬁrst
fraction of the [Ru(ser)(dppb)(bipy)]PF6 complex is close to the
potential of the [Ru(gly)(dppb)(bipy)]PF6 complex (1038 mV), sug-
gesting that these two species have the same conformation. Also,
the difference in the chemical shifts of the doublets found for the
ﬁrst fraction of the serine complex is 8.1 (Fig. 5), while the same
difference found for fraction two is 4.9. Given that the difference
between the doublets for the glycine complex is 7.2, this supports
our suggestion that the complex with glycine has the same confor-
mation as that obtained in the ﬁrst isolated fraction of the complex
with the amino acid serine.
3.4. Cytotoxicity
The tumor cell lines were exposed to the amino acid complexes
for a period of 48 h, in order to allow them time to reach the bio-
logical target. The IC50 (drug concentration at which 50% of the
cells are viable relative to the control values, calculated from the
dose-survival curves obtained with the MTT assay performed after
48 h of drug treatment, are shown in Table 5. For comparison, the
Fig. 5. 31P{1H} NMR spectra of the fractions of the [Ru(ser)(dppb)(bipy)]PF6, separated by HPLC, in CH2Cl2. Left ﬁrst fraction; right, second fraction.
Fig. 6. Cyclic voltammogram (PTBA 0.1 mol L1; CH2Cl2; Ag/AgCl; working electrode Pt; 100 mV s1) and differential pulse voltammogram (70 mV.s1) of
[Ru(Lser)(dppb)(bipy)]PF6.
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cytotoxicity of cisplatin was assessed under the same experimental
conditions.
The new amino acid complexes (1–9) showed good activity
against the human MDA-MB-231 and DU 145 cell lines and against
the mouse, Ehrlich, cell line. Compared with cisplatin (reference
metallodrug), the amino acid complexes obtained in these studies
were, in general, more active against these three tumor cell lines,
indicating their potentiality as antitumor agents. The cellular stud-
ies were performed with mixtures of the two isomers, except for
the [Ru(ser)(dppb)(bipy)]PF6 complex. In this case the two isomers
were isolated by HPLC experiments and the studies were per-
formed with the isolated fractions, showing for both fractions the
same IC50 results, within the experimental error, for all four cells
tested.
Most ruthenium-containing complexes studied for their antitu-
moral activity, reported in the literature, have a pair of cis-orien-
tated chloro ligands and some reports indicate the possibility of
a mechanism involving DNA binding. This is probably not the case
of the complexes used in this study, since they are hexacoordinat-
ed and very stable in the incubation solution. However, one possi-
ble mechanism to explain the activity of the amino acid complexes
could be similar to those reported in the literature suggesting a
weak interaction of the ruthenium compounds with DNA [26,27].
Thus, in order to investigate whether this interaction could be part
of the mode of action of the amino acid ruthenium complexes,
experiments with CT-DNA were carried out.
The intrinsic binding constants (Kb) for complexes (1–9) were
determined and found to be in the range of 1.40  104–
1.80  104 M1, suggesting weak interaction between the com-
plexes and DNA. These values of Kb are lower than those found
for transition metallic complexes containing at least one intercalat-
ing ligand present binding constants in the order of 105–107 M1
[28,29]. In this case, the complex-DNA interaction may occur via
superﬁcial binding, mainly through the carboxylate and amino
groups of the amino acids, which could form hydrogen bonds with
the DNA base pairs, contributing to the overall hyperchromism
[30].
4. Conclusions
In this study, nine new amino acid/diphosphine ruthenium
complexes, of general formula [Ru(AA-H)(dppb)(bipy)]PF6, were
synthesized and characterized. The IR data suggested that the car-
boxylate groups of the coordinated amino acids are unidentate
coordinated to the metal center. The X-ray structures of the glycine
and leucine complexes conﬁrmed this suggestion and showed that
the amino acids are coordinated to the metal center through the
carboxylate and amine groups. All the complexes, except the gly-
cine complex, formed two different diastereoisomers, as shown
by 31P{1H} NMR and conﬁrmed by X-ray diffraction. The amino
acid complexes exhibited an oxidation potential (RuII/RuIII) close
to 1.0 V, against Ag/AgCl. The cytotoxic activities against the
MDA-MB-231 and DU 145 human tumor cell lines and the Ehrlich
mouse cell line indicated a high degree of cytotoxicity for the
amino acid complexes. Indeed the new complexes are, in general,
more active than cisplatin (reference metallodrug) against these
tumor cells and less active against the healthy L-929 mouse cell.
The amino acid complexes (1–9) are stable in the biological med-
ium and thus, such as hexacoordinated species, their mechanism
of action against the tumor cells is probably due to superﬁcial
interaction with the DNA. Indeed, determination of the intrinsic
binding constants of the complexes with the CT-DNA suggests
weak interaction between of the complexes and this biomolecule,
possibly by hydrogen bonding.
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